Holen Sie sich die Stockscreener-App
1.05
0.00%
0.00
Vorhandelsmarkt:
1.05
Schlusskurs vom Vortag:
$1.05
Offen:
$1.06
24-Stunden-Volumen:
504.39K
Relative Volume:
0.47
Marktkapitalisierung:
$4.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.90M
KGV:
-0.0051
EPS:
-206.0125
Netto-Cashflow:
$-12.75M
1W Leistung:
+3.96%
1M Leistung:
+6.05%
6M Leistung:
+525.00%
1J Leistung:
-87.90%
1-Tages-Spanne:
$1.015
$1.06
1-Wochen-Bereich:
$0.961
$1.07
52-Wochen-Spanne:
$0.1131
$9.60
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Firmenname
Allarity Therapeutics Inc
Sektor
Branche
Telefon
401-426-4664
Adresse
24 SCHOOL ST., 2ND FLOOR, BOSTON
Vergleichen Sie ALLR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.05 | 4.66M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten
No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register
2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - AccessWire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-08 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - AccessWire
2025-01-02 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Allarity Therapeutics stock hits 52-week low at $1.03 - Investing.com
Allarity Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - Longview News-Journal
Allarity Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Allarity Therapeutics stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Allarity Therapeutics stock hits 52-week low at $1.14 - Investing.com
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, I - GuruFocus.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus.com
Allarity Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Allarity's Phase 2 Cancer Drug Shows Promise: Patients Exceed 14-Month Treatment | ALLR Stock News - StockTitan
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - The Manila Times
Allarity Therapeutics Reports $18.5M Cash Position, Extended Runway in Q3 Results | ALLR Stock News - StockTitan
FINAL REMINDER ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Allarity Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Business Wire
FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Finanzdaten der Allarity Therapeutics Inc-Aktie (ALLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):